Biocon Foundation and IISc commemorate World Head & Neck Cancer Day

This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines

Zambon launches intravenous formulation of Fluimucil

The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile

Sai Life Sciences commences commercial operation of 2nd phase in Bidar

This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility

Fortis Healthcare launches Fortis Institute of Genomic Medicine

Genomics is transforming the future of modern medicine and treatment modalities across specialties

Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million

Indoco’s clinical research organisation ‘AnaCipher’ completes USFDA inspection

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma

Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program

Tolebrutinib meets primary endpoint in HERCULES phase 3 study

Phase 3 study results will form the basis for future discussions with global regulatory authorities